Preparation of live attenuated mumps virus for a vaccine

• US 4,324,861 A
• Filed: 12/06/1979
• Issued: 04/13/1982
• Est. Priority Date: 05/04/1979
• Status: Expired due to Term

• Current Assignee: The Research Foundation for Microbial Diseases of Osaka University
• Original Assignee: The Research Foundation for Microbial Diseases of Osaka University
• Inventors: Kan, Takayoshi
• Primary Examiner(s): Rosen, Sam
• Application Number:
  US06/100,957
• Time in Patent Office: 859 Days
• Field of Search: 435/237, 424/89
• US Class Current: 435/237
• CPC Class Codes: A61K 2039/5254 avirulent or attenuated
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61K 39/165 Mumps or measles virus
• CPC Class Codes: C12N 2760/18734 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

A live attenuated mumps virus vaccine is prepared by cultivating a wild mumps virus strain for 1-18 serial passages in a first living cell to attenuate the virus, and then cultivating the attenuated virus in a second living cell for at least one serial passage to propagate and adapt the virus to the cell. The cell is selected from embryonated hen'"'"'s egg amnion, embryonated hen'"'"'s egg chorio-allantoic membrane, chick embryo fibroblast and human diploid cell. Quail embryo fibroblast is also employed. The vaccine prepared has strong immunogenecity and is safe.

Claims

1. A method of preparing a live attenuated mumps virus for a vaccine comprising:

incubating a wild mumps virus strain in a living cell selected from the group consisting of embryonated hen'"'"'s egg chorio-allantoic membrane, chick embryo fibroblast and human diploid cell for 1-18 passages sufficient to attenuate the virus, and

subjecting the thus attenuated virus to successive cultivation in a living cell selected from the group consisting of embryonated hen'"'"'s egg amnion, embryonated hen'"'"'s egg chorio-allantoic membrane and human diploid cell to propagate the virus.

2. A method according to claim 1 wherein the second cell is embryonated hen'"'"'s egg amnion.

3. A method according to claim 1 wherein the virus is attenuated through 8-14 serial passages.

4. A method according to claim 1 wherein the attenuation of virus includes the steps of

inoculating the virus into an amniotic cavity,

cultivating the virus for 5-6 days, and

harvesting the amniotic fluid, from which the attenuated virus is obtained.

5. A method according to claim 4 wherein the attenuation is carried out for 8-14 serial passages.

6. A method according to claim 1 wherein the second cell is embryonated hen'"'"'s egg amnion, and the propagation of virus includes the steps of inoculating the virus into an amniotic cavity, cultivating the virus for 5-6 days, and harvesting the amniotic fluid, from which the propagated virus is obtained.

7. A method of preparing a live attenuated mumps virus for a vaccine comprising:

incubating a wild mumps virus strain in a living cell selected from the group consisting of embryonated hen'"'"'s egg chorio-allantoic membrane, chick embryo fibroblast and human diploid cell for 1-18 passages sufficient to attenuate the virus;

and

subjecting the thus attenuated virus to successive cultivation in a living human diploid cell to propagate the virus.

8. A method of preparing a live attenuated mumps virus for a vaccine comprising:

incubating a wild mumps virus strain in a living human diploid cell for 1-18 serial passages sufficient to attenuate the virus; and

subjecting the thus attenuated virus to successive cultivation in a living cell selected from the group consisting of embryonated hen'"'"'s egg amnion, embryonated hen'"'"'s egg chorio-allantoic membrane and human diploid cell to propagate the virus.